Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
By J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. Kieback, S. Kaye, L. Gianni, Adrian L. Harris, T. Björk and 5 more. Journal of Clinical Oncology, 2002
842 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/6c98c0c90789c7ad19758cf47d33d4b3c746d265
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. (2005, background): “In clinical studies, the acneiform eruption caused by EGFR inhibitors is usually classified according to the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC v2.0) [2, 3, 5, 12 , 14, 15, 18] (Table 2) or the more recent National Cancer Institute Common Terminology Criteria fo”
- ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “fcgi?db=genec changes in STAT3 activity; and a decreased proliferation index, associated in some cases with increased apoptosi”